RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Absorption inhibition and enhancement of elimination of sustained-release theophylline tablets by oral activated charcoal.

The effect of orally administered activated charcoal (OAC) on the first 12 hours of absorption and elimination of sustained-release theophylline tablets (SRT) was investigated in 20 normal children ages 8 to 18 years. The theophylline absorption-elimination characteristic of all subjects was determined after ingestion of 10 mg/kg SRT. Blood for theophylline was sampled at 0, two, four, six, eight, ten, 12, and 24 hours. After a 72-hour theophylline washout period, the subjects were assigned randomly to one of four study groups and received 10 mg/kg SRT. OAC then was given as a single dose one hour later to Group 1 subjects. Group 2 subjects took four doses of OAC at three-hour intervals beginning at one hour after SRT dosing. Group 3 subjects also received four doses of OAC at three-hour intervals with the first dose given three hours after SRT; Group 4 subjects received three doses at similar intervals with the first dose administered six hours after SRT dosing. OAC administration reduced the 12-hour area under the concentration time curve for theophylline (AUC) by 61% in Group 1, by 68% in Group 2, by 37% in Group 3, and by 18% in Group 4. The differences in AUC between treated and untreated subjects were significant at P less than .01 for Group 1, at P less than .001 for Group 2, at P less than .02 for Group 3, and not significant for Group 4. These data indicate that early OAC administration can inhibit SRT absorption significantly and enhance elimination of previously absorbed theophylline.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app